04/06/2026 Gilead Sciences and Lakefront completed the acquisition of Ouro Medicines to further expand inflammation pipeline Gilead Sciences and Lakefront completed the acquisition of Ouro Medicines to further expand inflammation pipeline (Ref) Gilead Sciences and Lakefront Biotherapeutics announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition added gamgertamig